Cellular mechanisms of acquired drug resistance against regorafenib in colon cancer cells.
Deepu Sharma, Fayyaz Rasool, Binayak Kumar, Rohit Verma, Ashutosh Singh, Sri Krishna Jayadev Magani
This study identifies mTOR/eIF2 signaling as a critical driver of regorafenib resistance in colorectal cancer and shows that targeting these pathways can resensitize resistant cells.
bioRxiv · Feb 5, 2026 · PreprintCancer Biology